Actively Recruiting

Phase 1
Phase 2
Age: 40Years +
All Genders
NCT07113067

Accelerated rTMS vs. Sham for Stroke Apathy

Led by Medical University of South Carolina · Updated on 2025-10-22

40

Participants Needed

1

Research Sites

98 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.

CONDITIONS

Official Title

Accelerated rTMS vs. Sham for Stroke Apathy

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 40 years old or greater
  • Right- or left-hemisphere ischemic or hemorrhagic stroke with at least 6 months chronicity
  • Symptomatic apathy confirmed by Apathy Evaluation Scale score of 39 or higher by participant or caregiver
  • Ability to participate in psychometric testing and cognitive tasks
  • Intact cortex at the TMS target site confirmed by pre-treatment MRI
  • Ability to have a co-participant/caregiver who meets study criteria
Not Eligible

You will not qualify if you...

  • Primary extra-axial hemorrhage without ischemic stroke or intraparenchymal hemorrhage
  • Other neurological disorders affecting motor or cognitive function (e.g. dementia)
  • Moderate or severe global aphasia
  • Visual impairment preventing completion of cognitive tasks
  • Contraindications to MRI or TMS including metal or sensitive implants
  • Pregnancy (confirmed by urine pregnancy test if applicable)
  • History of seizure disorder
  • Scalp lesion, wound, bone defect, or hemicraniectomy
  • Claustrophobia preventing MRI
  • Active substance use disorder
  • Psychotic disorders
  • Bipolar 1 Disorder
  • Acute suicidality or suicide attempt in past year
  • Co-participant/caregiver unable to engage with study procedures requiring their input

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of South Carolina Brain Stimulation Lab

Charleston, South Carolina, United States, 29403

Actively Recruiting

Loading map...

Research Team

P

Parneet Grewal, MD

CONTACT

L

Lisa McTeague, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here